The McClung Lab
(7/25/14)The McClung Lab is focused on understanding the molecular mechanisms of angiogenesis and vascular remodeling in both physiologic and pathologic processes, including: exercise, peripheral artery disease (PAD), atherosclerosis, cardiac and cerebral ischemia, diabetes, and cancer. The lab is interested in how genetic variation may direct the integration of individual cellular responses to ischemic insult, resulting in differential manifestations of tissue pathology in both pre-clinical models and in clinical patient populations. On a deeper level, the lab is studying how single nucleotide polymorphisms affect autophagy, mitochondria, oxidative stress, and signal transduction by endothelial receptor tyrosine kinase (RTKs) in different cell types (skeletal muscle, endothelial, progenitor, smooth muscle, fibroblast). Therapeutic strategies targeting the vasculature in cardiovascular disease have met with little success, and those aimed at preventing tumor angiogenesis result in significant side effects that often result in forced cessation of therapy. The McClung lab hopes to lay the foundation for the development of novel diagnostic and therapeutic tools for tissue ischemia and aid in the refinement of current anti-angiogenic therapies for cancer. The lab currently consists of Dr. McClung (PI), Cameron Schmidt (Graduate Student). Tom Green (currently in Oncology as a Research Associate) will be joining the lab August 1.